Latest news
- Sustainability13 May 2024
Prioritizing Mental Health: Adalvo's Commitment to Employee Wellbeing
In today's fast-paced world, mental health awareness has become more crucial than ever. At Adalvo, we recognize the importance of fostering a supportive and nurturing environment where our employees' mental...
- Business10 May 2024
Adalvo Addresses Traveller’s Diarrehea With Rifamycin SV MMX
Adalvo provides an update on Rifamycin SV MMX, an EU-approved product, with Marketing Authorizations (MAs) secured in selective countries.
- Business08 May 2024
Adalvo Restarts DCP Procedure for Mirabegron Prolonged Release Tablets
Adalvo announces the restart of the DCP procedure for Mirabegron 50 mg prolonged-release tablets with an anticipated EU Marketing Authorisation Approval date in July 2024. Developed based on the reference brand...
- Business07 May 2024
Navigating Diabetes: Adalvo's Tailored Solutions
Diabetic care presents a complex challenge, requiring diverse treatment options to improve patient outcomes effectively. Adalvo's diabetes portfolio offers advanced therapies designed to address the underlying conditions of the disease. From...
- Business03 May 2024
Adalvo Restarts DCP Procedure for Desogestrel/Ethinylestradiol Film-Coated Tablets
Adalvo announces the restart of the DCP procedure for Desogestrel/Ethinylestradiol 150/20 micrograms film-coated tablets, with an anticipated EU approval date for August 2024. Developed based on the reference brand Mercilon film-coated tablets,...
- Business29 April 2024
Adalvo Q1 2024 Reports: Over 325 MA Submissions and 360 Approvals
In Q1 2024, Adalvo successfully submitted a total of 329 Marketing Authorisation (MA) applications, spanning 55 countries and representing collaborative efforts with 31 strategic partners. On top of this, Adalvo achieved...
- Business26 April 2024
Adalvo Recognizes World IP Day 2024: Prioritizing Health and Well-being
Adalvo acknowledges and participates in World IP Day 2024, joining the global community in celebrating innovation and creativity in intellectual property (IP). This year's theme, "𝐈𝐏 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐒𝐃𝐆𝐬: 𝐁𝐮𝐢𝐥𝐝𝐢𝐧𝐠...
- Business22 April 2024
Adalvo Introduces Apalutamide to its Oncology Portfolio
Adalvo is excited to announce the introduction of Apalutamide to our Oncology Portfolio. Based on the reference brand Erleada, Apalutamide, available in film-coated tablet form with strengths of 60mg and 240mg, is a...
- Business17 April 2024
Adalvo advances on Ceftazidime + Avibactam
Adalvo is strategically advancing in the development of Ceftazidime + Avibactam, a complex and differentiated antibiotic combination, aiming to be First To File in all major markets. Based on the...
- Achievements15 April 2024
Adalvo Sets New Performance Record in March: Highest Batch Release Achieved
Adalvo proudly announces a significant milestone in its operational performance, setting a new record by releasing a total of 221 batches during March 2024, surpassing previous benchmarks by 42%. This achievement showcases...
- Business12 April 2024
Pregabalin Prolonged Release Tablets Launched in Germany
Adalvo and Aristo Pharma proudly announce the successful launch of Pregabalin Prolonged Release Tablets in Germany, solidifying their position as the first to introduce this innovative medication in the European...
- Business09 April 2024
Mirabegron/Solifenacin PR Tablets Added To Adalvo's Product List
Adalvo proudly announces the addition of Mirabegron/Solifenacin Prolonged Release Tablets to our product list, set to be submitted for regulatory approval in Q1 2025. Developed in collaboration with one of our strategic...
- Business08 April 2024
Aztiq Acquires 100% Ownership of Adalvo from PTT, Backed by Investor Metric Capital Partners to Accelerate Further Growth
Aztiq, a prominent healthcare investor led by Founder and Chairman Róbert Wessman, has finalized an agreement in Q1 2024 with Innobic (Asia) Company Limited (“Innobic”), the life science arm of...
- Business05 April 2024
Adalvo Restarts DCP Procedure for Empagliflozin Film-Coated Tablets
Adalvo is pleased to announce the restart of the EU Marketing Authorisation Approval for Empagliflozin 10mg and 25mg film-coated tablets with an anticipated approval date in July 2024. Our product has...
- Business04 April 2024
Adalvo Launches Desmopressin in Multiple Countries Across Europe
Adalvo is thrilled to announce the successful launch of Desmopressin in multiple countries across Europe, in collaboration with key strategic partners. Developed based on the reference brand Minirin Melt from Ferring, Desmopressin...
- Business27 March 2024
Adalvo Announces Successful Completion of Pilot BE Study for Fidaxomicin
Adalvo is delighted to announce the successful completion of the FED and Fasting Pilot BE Study for Fidaxomicin Film Coated Tablets 200mg. Developed in collaboration with one of our strategic partners,...
- Business26 March 2024
Alectinib Tablets Added To Adalvo's Product List
Adalvo proudly announces the addition of Alectinib 300, 450, and 600mg tablets to our product list. Our product, being developed based on the reference brand Alecensa 150mg hard capsules, will serve as...
- Business20 March 2024
Adalvo Restarts Regulatory Procedures for Ethinylestradiol + Drospirenone DCP
Adalvo is pleased to announce the restart of the DCP procedure for Ethinylestradiol + Drospirenone 0.03 mg/3 mg, with an anticipated approval date in July 2024. Based on the reference brand...
- Business15 March 2024
Lenvatinib Oral Solution Added To Adalvo's Product Portfolio
Adalvo proudly announces the addition of Lenvatinib 4mg/ml Oral Solution to our product portfolio. Our product, developed based on the reference brand LENVIMA, serves as a vital treatment for Differentiated Thyroid...
- Business13 March 2024
Adalvo Restarts Regulatory Procedures for Dalbavancin DCP with Anticipated European Approval in May 2024
Adalvo is delighted to announce the restart of the DCP procedure for Dalbavancin powder, with an estimated approval date in May 2024. This antibiotic niche product has been developed based on...
- Business08 March 2024
Adalvo Receives Marketing Authorization Approval for Pomalidomide Hard Capsules in Israel
Adalvo is pleased to announce the successful Marketing Authorization (MA) approval of Pomalidomide Hard Capsules 1/2/3/4mg in Israel. Our product, based on the reference brand Imnovid, is indicated for the...